Corrections: Effect of long-term omega 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints (MAPT): a randomised, placebo-controlled trial (The Lancet Neurology (2017) 16(5) (377–389) (S1474442217300406) (10.1016/S1474-4422(17)30040-6);Effect of long-term omega 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints (MAPT): a randomised, placebo-controlled trial

The Lancet Neurology

Volumn 16, Issue 5, 2017, Pages 377-389

  Andrieu, Sandrine ^a,b,c,w   Guyonnet, Sophie ^a,b,d,w   Coley, Nicola ^a,b,c   Cantet, Christelle ^a,b,d,w   Bonnefoy, Marc ^e,w   Bordes, Serge ^f,w   Bories, Lawrence ^g,w   Cufi, Marie Noëlle ^h   Dantoine, Thierry ^i,w   Dartigues, Jean François ^j,w   Desclaux, Françoise ^k,w   Gabelle, Audrey ^l,m,w   Gasnier, Yannick ^f,w   Pesce, Alain ^n,w   Sudres, Kristel ^o,w   Touchon, Jacques ^l,p,w   Robert, Philippe ^q,w   Rouaud, Olivier ^r,w   Legrand, Philippe ^s   Payoux, Pierre ^d,t,w   Caubere, Jean Paul ^u   Weiner, Michael ^v   Carrié, Isabelle ^d,w   Ousset, Pierre Jean ^a,b,d,w   Vellas, Bruno ^a,b,d,w   Brigitte, Lauréane ^w   Faisant, Catherine ^w   Lala, Françoise ^w   Delrieu, Julien ^w   Villars, Hélène ^w   Combrouze, Emeline ^w   Badufle, Carole ^w   Zueras, Audrey ^w   Morin, Christophe ^w   Van Kan, Gabor Abellan ^w   Dupuy, Charlotte ^w   Rolland, Yves ^w   Caillaud, Céline ^w   Fougère, Bertrand ^w   Willis, Sherry ^w   Belleville, Sylvie ^w   Gilbert, Brigitte ^w   Fontaine, Francine ^w   Marcet, Isabelle ^w   Delva, Fleur ^w   Foubert, Alexandra ^w   Cerda, Sandrine ^w   Noëlle Cuffi, Marie ^w   Costes, Corinne ^w   Manckoundia, Patrick ^w   Quipourt, Valérie ^w   Marilier, Sophie ^w   Franon, Evelyne ^w   Pader, Marie Laure ^w   Basset, Marie France ^w   Lapoujade, Bruno ^w   Faure, Valérie ^w   Li, Michael ^w   Tong, Yung ^w   Malick Loiseau, Christine ^w   Cazaban Campistron, Evelyne ^w   Blatge, Colette ^w   Laubarie Mouret, Cécile ^w   Saulnier, Isabelle ^w   Clément, Jean Pierre ^w   Picat, Marie Agnès ^w   Bernard Bourzeix, Laurence ^w   Willebois, Stéphanie ^w   Désormais, Iléana ^w   Cardinaud, Noëlle ^w   Livet, Pierre ^w   Rebaudet, Pascale ^w   Gédéon, Claire ^w   Burdet, Catherine ^w   Terracol, Flavien ^w   Roth, Stéphanie ^w   Chaillou, Sylvie ^w   Louchart, Sandrine ^w   Lebrun, Nicolas ^w   Barro Belaygues, Nadège ^w   Bennys, Karim ^w   Romano, Aurélia ^w   Touati, Lynda ^w   Marelli, Cécilia ^w   Pays, Cécile ^w   Le Duff, Franck ^w   Gervais, Claire ^w   Gonfrier, Sébastien ^w   Begorre, Danièle ^w   Carpuat, Christian ^w   Khales, Khaled ^w   Lefebvre, Jean François ^w   El Idrissi, Samira Misbah ^w   Skolil, Pierre ^w   Salles, Jean Pierre ^w   Dufouil, Carole ^w   Lehéricy, Stéphane ^w   Chupin, Marie ^w   Mangin, Jean François ^w   Bouhayia, Ali ^w   Allard, Michèle ^w   Ricolfi, Frédéric ^w   Dubois, Dominique ^w   Paule, Marie ^w   Martel, Bonceour ^w   Cotton, François ^w   Bonafé, Alain ^w   Chanalet, Stéphane ^w   Hugon, Françoise ^w   Bonneville, Fabrice ^w   Cognard, Christophe ^w   Chollet, François ^w   Voisin, Thierry ^w   Peiffer, Sophie ^w   Hitzel, Anne ^w   Zanca, Michel ^w   Monteil, Jacques ^w   Darcourt, Jacques ^w   Molinier, Laurent ^w   Derumeaux, Hélène ^w   Costa, Nadège ^w   Vincent, Christian ^w   Perret, Bertrand ^w   Vinel, Claire ^w   Olivier Abbal, Pascale ^w   more..

^a Faculté de Médecine Centre Hospitalo universitaire   (France)

^b UNIVERSITÉ PAUL SABATIER   (France)

^c TOULOUSE UNIVERSITY HOSPITAL   (France)

^d CHU PURPAN   (France)

^e CENTRE HOSPITALIER LYON SUD   (France)

^f Hospital of Tarbes   (France)

^g Hospital of Foix   (France)

^h Geriatrics Department   (France)

ⁱ LIMOGES UNIVERSITY HOSPITAL   (France)

^j BORDEAUX UNIVERSITY HOSPITAL   (France)

^k Geriatrics Department   (France)

^l MONTPELLIER UNIVERSITY HOSPITAL   (France)

^m INSERM   (France)

ⁿ CENTRE HOSPITALIER PRINCESSE GRACE   (Monaco)

^o Hospital of Montauban   (France)

^p INSERM   (France)

^q University of Côte d Azur   (France)

^r DIJON UNIVERSITY HOSPITAL   (France)

^s AGROCAMPUS OUEST   (France)

^t UPS   (France)

^u INSTITUT DE RECHERCHE PIERRE FABRE   (France)

^v UNIVERSITY OF CALIFORNIA   (United States)

^w NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

DOCOSAHEXAENOIC ACID; ICOSAPENTAENOIC ACID; OMEGA 3 FATTY ACID; PLACEBO;

AGED; ARTICLE; BREAST DISEASE; CARDIOVASCULAR RISK; COGNITION; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DIET SUPPLEMENTATION; DIGIT SYMBOL SUBSTITUTION TEST; DRUG EFFICACY; FEMALE; FOLLOW UP; FOOD SAFETY; FRANCE; GAIT; GASTROINTESTINAL DISEASE; HEARING DISORDER; HEART DISEASE; HUMAN; INTENTION TO TREAT ANALYSIS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; MENTAL DISEASE; METABOLIC DISORDER; MINI MENTAL STATE EXAMINATION; MONACO; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; NUTRITION; NUTRITIONAL DISORDER; OUTCOME ASSESSMENT; PHYSICAL ACTIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; UROGENITAL TRACT DISEASE; VASCULAR DISEASE; VISION; VISUAL DISORDER; CLINICAL TRIAL; COGNITIVE THERAPY; DIETARY SUPPLEMENT; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; KINESIOTHERAPY; MEMORY DISORDERS; NEUROPSYCHOLOGICAL TEST; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; COGNITION; COGNITIVE THERAPY; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; EXERCISE THERAPY; FATTY ACIDS, OMEGA-3; FEMALE; HUMANS; MALE; MEMORY DISORDERS; NEUROPSYCHOLOGICAL TESTS; TREATMENT OUTCOME;

EID: 85016730734     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(17)30090-X     Document Type: Erratum

References (41)

1. 1 Winblad, B, Amouyel, P, Andrieu, S, et al. Defeating Alzheimer's disease and other dementias: a priority for European science and society. Lancet Neurol 15 (2016), 455–532.
2. 2 Andrieu, S, Coley, N, Lovestone, S, Aisen, PS, Vellas, B, Prevention of sporadic Alzheimer's disease: lessons learned from clinical trials and future directions. Lancet Neurol 14 (2015), 926–944.
3. 3 Heude, B, Ducimetiere, P, Berr, C, Cognitive decline and fatty acid composition of erythrocyte membranes—the EVA Study. Am J Clin Nutr 77 (2003), 803–808.
4. 4 Schaefer, EJ, Bongard, V, Beiser, AS, et al. Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease: the Framingham Heart Study. Arch Neurol 63 (2006), 1545–1550.
5. 5 Tan, ZS, Harris, WS, Beiser, AS, et al. Red blood cell omega-3 fatty acid levels and markers of accelerated brain aging. Neurology 78 (2012), 658–664.
6. 6 Vellas, B, Carrie, I, Gillette-Guyonnet, S, et al. Mapt study: a multidomain approach for preventing Alzheimer's disease: design and baseline data. J Prevent Alzheimer Dis 1 (2014), 13–22.
7. 7 Lawton, MP, Scales to measure competence in everyday activities. Psychopharmacol Bull 24 (1988), 609–614.
8. 8 Abellan van Kan, G, Rolland, Y, Andrieu, S, et al. Gait speed at usual pace as a predictor of adverse outcomes in community-dwelling older people an International Academy on Nutrition and Aging (IANA) Task Force. J Nutr Health Aging 13 (2009), 881–889.
9. 9 Alfaro-Acha, A, Al Snih, S, Raji, MA, Markides, KS, Ottenbacher, KJ, Does 8-foot walk time predict cognitive decline in older Mexicans Americans?. J Am Geriatr Soc 55 (2007), 245–251.
10. 10 Studenski, S, Perera, S, Patel, K, et al. Gait speed and survival in older adults. JAMA 305 (2011), 50–58.
11. 11 Folstein, MF, Folstein, SE, McHugh, PR, “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12 (1975), 189–198.
12. 12 Katz, S, Ford, AB, Moskowitz, RW, Jackson, BA, Jaffe, MW, Studies of illness in the aged. The index of ADL: a standardized measure of biological and psychosocial function. JAMA 185 (1963), 914–919.
13. 13 Gillette Guyonnet, S, Abellan Van Kan, G, Andrieu, S, et al. Prevention of progression to dementia in the elderly: rationale and proposal for a health-promoting memory consultation (an IANA Task Force). J Nutr Health Aging 12 (2008), 520–529.
14. 14 Hercberg, S, Chat-Yung, S, Chaulia, M, The French National Nutrition and Health Program: 2001–2006–2010. Int J Public Health 53 (2008), 68–77.
15. 15 Grober, E, Buschke, H, Crystal, H, Bang, S, Dresner, R, Screening for dementia by memory testing. Neurology 38 (1988), 900–903.
16. 16 Wechsler, D, Wechsler adult intelligence scale—revised, 1981, Psychological Corp, New York.
17. 17 Cardebat, D, Doyon, B, Puel, M, Goulet, P, Joanette, Y, Formal and semantic lexical evocation in normal subjects. Performance and dynamics of production as a function of sex, age and educational level. Acta Neurol Belg 90 (1990), 207–217 (in French).
18. 18 Donohue, MC, Sperling, RA, Salmon, DP, et al. The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. JAMA Neurol 71 (2014), 961–970.
19. 19 Reitan, R, Validity of the Trail Making Test as an indicator of brain damage. Percept Mot Skills 8 (1958), 271–276.
20. 20 McNair, D, Kahn, R, Self-assessment of cognitive deficits. Crook, T, Ferris, A, Baltus, RE, (eds.) Assessment in clinical psychopharmacology, 1983, Mark Powley, New Cannan, CT, 137–143.
21. 21 Guralnik, JM, Ferrucci, L, Pieper, CF, et al. Lower extremity function and subsequent disability: consistency across studies, predictive models, and value of gait speed alone compared with the short physical performance battery. J Gerontol A Biol Sci Med Sci 55 (2000), M221–M231.
22. 22 Galasko, D, Bennett, DA, Sano, M, et al. ADCS Prevention Instrument Project: assessment of instrumental activities of daily living for community-dwelling elderly individuals in dementia prevention clinical trials. Alzheimer Dis Assoc Disord 20:suppl 3 (2006), S152–S169.
23. 23 Hughes, CP, Berg, L, Danziger, WL, Coben, LA, Martin, RL, A new clinical scale for the staging of dementia. Br J Psychiatry 140 (1982), 566–572.
24. 24 Fried, LP, Ferrucci, L, Darer, J, Williamson, JD, Anderson, G, Untangling the concepts of disability, frailty, and comorbidity: implications for improved targeting and care. J Gerontol A Biol Sci Med Sci 59 (2004), 255–263.
25. 25 Yesavage, JA, Brink, TL, Rose, TL, et al. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res 17 (1982), 37–49.
26. 26 Payoux, P, Delrieu, J, Gallini, A, et al. Cognitive and functional patterns of nondemented subjects with equivocal visual amyloid PET findings. Eur J Nucl Med Mol Imaging 42 (2015), 1459–1468.
27. 27 Amieva, H, Mokri, H, Le Goff, M, et al. Compensatory mechanisms in higher-educated subjects with Alzheimer's disease: a study of 20 years of cognitive decline. Brain 137 (2014), 1167–1175.
28. 28 Kivipelto, M, Ngandu, T, Laatikainen, T, Winblad, B, Soininen, H, Tuomilehto, J, Risk score for the prediction of dementia risk in 20 years among middle aged people: a longitudinal, population-based study. Lancet Neurol 5 (2006), 735–741.
29. 29 Fleisher, AS, Chen, K, Liu, X, et al. Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. Arch Neurol 68 (2011), 1404–1411.
30. 30 Hochberg, Y, A sharper Bonferroni procedure for multiple tests of significance. Biometrika 75 (1988), 800–802.
31. 31 Ngandu, T, Lehtisalo, J, Solomon, A, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet 385 (2015), 2255–2263.
32. 32 Dangour, AD, Allen, E, Elbourne, D, et al. Effect of 2-y n-3 long-chain polyunsaturated fatty acid supplementation on cognitive function in older people: a randomized, double-blind, controlled trial. Am J Clin Nutr 91 (2010), 1725–1732.
33. 33 Van de Rest, O, Geleijnse, JM, Kok, FJ, et al. Effect of fish oil on cognitive performance in older subjects: a randomized, controlled trial. Neurology 71 (2008), 430–438.
34. 34 Yurko-Mauro, K, McCarthy, D, Rom, D, et al. Beneficial effects of docosahexaenoic acid on cognition in age-related cognitive decline. Alzheimers Dement 6 (2010), 456–464.
35. 35 US Dept of Health and Human Services US Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry. Alzheimer's disease: developing drugs for the treatment of early stage disease (draft guidance). http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM338287.pdf (accessed March 16, 2017).
36. 36 Burnham, SC, Raghavan, N, Wilson, W, et al. Novel statistically-derived composite measures for assessing the efficacy of disease-modifying therapies in prodromal Alzheimer's disease trials: an AIBL study. J Alzheimers Dis 46 (2015), 1079–1089.
37. 37 European Medicines Agency. Discussion paper on the clinical investigation of medicines for the treatment of Alzheimer's disease and other dementias, 2014, European Medicines Agency, London.
38. 38 Coley, N, Gallini, A, Ousset, PJ, Vellas, B, Andrieu, S, Evaluating the clinical relevance of a cognitive composite outcome measure: an analysis of 1414 participants from the 5-year GuidAge Alzheimer's prevention trial. Alzheimers Dement 12 (2016), 1216–1225.
39. 39 Pottala, JV, Yaffe, K, Robinson, JG, Espeland, MA, Wallace, R, Harris, WS, Higher RBC EPA + DHA corresponds with larger total brain and hippocampal volumes: WHIMS-MRI study. Neurology 82 (2014), 435–442.
40. 40 Sun, Q, Ma, J, Campos, H, Hankinson, SE, Hu, FB, Comparison between plasma and erythrocyte fatty acid content as biomarkers of fatty acid intake in US women. Am J Clin Nutr 86 (2007), 74–81.
41. 41 Amieva, H, Jacqmin-Gadda, H, Orgogozo, JM, et al. The 9 year cognitive decline before dementia of the Alzheimer type: a prospective population-based study. Brain 128 (2005), 1093–1101.